Numinus Wellness Commends Health Canada on Special Access Programme Amendments to Restore Potential Access to Psychedelic Medicines Post published:December 22, 2021 Post category:Press Release
Numinus Wellness Inc. to Commence Trading on the TSX on December 16, 2021 Post published:December 14, 2021 Post category:Press Release
Numinus Wellness Inc. Reports Q4 and Year End 2021 Results Post published:December 9, 2021 Post category:Press Release
Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans Post published:November 29, 2021 Post category:Press Release
Numinus Receives Conditional Approval to Graduate to the Toronto Stock Exchange Post published:November 26, 2021 Post category:Press Release
Numinus Announces Departure of Stacey Wallin Post published:November 25, 2021 Post category:Press Release
Numinus to Host Q4 and 2021 Annual Results Conference Call on December 9, 2021 Post published:November 22, 2021 Post category:Press Release
Numinus to Begin Trading on the OTC Under Symbol NUMIF Post published:November 19, 2021 Post category:Press Release
Numinus to Host Extension of MAPS-Sponsored MDMA-Assisted Therapy for PTSD Trials Post published:November 10, 2021 Post category:Press Release
Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product Post published:October 20, 2021 Post category:Press Release